Levofloxacin Hydrochloride Tablets

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about twice that of ofloxacin. Its main mechanism of action is to inhibit the activity of bacterial DNA gyrase (bacterial topoisomerase II) and hinder bacterial DNA replication. This product has the characteristics of a broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Serratia, Proteus, Shigella, Salmonella, Citrobacter, Acinetobacter, and Gram-negative bacteria such as Pseudomonas aeruginosa, Haemophilus influenzae, and Neisseria gonorrhoeae. It also has good antibacterial effects on some methicillin-sensitive Staphylococci, Streptococcus pneumoniae, Streptococcus pyogenes, hemolytic Streptococci, and Legionella, Mycoplasma, and Chlamydia, but has poor effects on anaerobic bacteria and enterococci.

Levofloxacin Hydrochloride

This product is a white film-coated tablet, which appears off-white or light yellow after removing the film.

This product is suitable for the following mild and moderate infections caused by sensitive bacteria; respiratory system infections: acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bronchiolitis, bronchiectasis and infection, pneumonia, tonsillitis (peritonsillar abscess); urinary system infections: pyelonephritis, complicated urinary tract infection, etc.; reproductive system infections: acute prostatitis, acute epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected); skin and soft tissue infections: infectious impetigo, cellulitis, lymphangiitis (nodal inflammation), subcutaneous abscess, perianal abscess, etc.; intestinal infections: bacillary dysentery, infectious enteritis, salmonella enteritis, typhoid and paratyphoid; various infections in patients with sepsis, neutropenia and immunodeficiency; other infections: mastitis, trauma, burns and postoperative wound infection, abdominal cavity infection (metronidazole can be used in combination when necessary), cholecystitis, cholangitis, bone and joint infection and ENT infection, etc.

Oral administration: 0.1-0.2g per time for adults, twice a day. For patients with severe conditions, it can be increased to three times a day.

During medication, symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, abdominal distension, insomnia, dizziness, headache and other neurological symptoms, as well as rash, itching and other symptoms may occur. Transient liver function abnormalities may also occur, such as increased serum transaminase and increased serum total bilirubin. The incidence of the above adverse reactions is between 0.1% and 5%. Occasionally, blood urea nitrogen rises, fatigue, fever, palpitations, abnormal taste, etc., which are generally tolerated and disappear quickly after the end of the treatment.

It is contraindicated for patients who are allergic to quinolones, pregnant or lactating women, and patients under 18 years of age.

Precautions for children: It is forbidden for children. Precautions for pregnancy and lactation: Pregnant and lactating women Precautions for the elderly: Elderly patients should use it with caution. Generally, 0.1g is used once, twice a day, and the interval between medications should be noted.

1. This product cannot be used in the same infusion tube with polyvalent metal ion solutions such as magnesium and calcium. 2. Avoid using it simultaneously with theophylline. If it is necessary to use it simultaneously, the blood concentration of theophylline should be monitored and the dosage should be adjusted accordingly. 3. When used simultaneously with warfarin or its derivatives, the prothrombin time or other coagulation tests should be monitored. 4. When used simultaneously with non-steroidal anti-inflammatory drugs, convulsions may be induced. 5. When used simultaneously with oral hypoglycemic drugs, hypoglycemia may be caused. Therefore, blood glucose concentration should be monitored during medication. Once hypoglycemia occurs, this product should be discontinued immediately and appropriate treatment should be given.

Keep away from light and store in sealed container.

0.1g (as levofloxacin)

24 months

Hubei Newland Pharmaceutical Co., Ltd.

• Founded in:

  2001-04-27

• Address:

  No. 36 Dongwu Avenue, Wujiashan Taiwanese Investment Zone, Dongxihu District, Wuhan (6)

• Tax NO.:

  91420112726149349L

• Registered Funds:

  30 million yuan

• Website:

  Log in to view

• Email:

  Log in to view